Kamada - High Quality Pharmaceuticals

May. 16, 2014

Kamada Announces Preliminary Results from Phase II/III Pivotal Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

May. 8, 2014

Kamada Reports First Quarter Financial Results

Upcoming Event

Kamada to participate at the ERS International Congress
Sep. 6-10, 2014

High Quality Pharmaceuticals

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology.
Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide.

Alpha-1

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition which can cause serious liver disease in children and liver and/or lung disease in adults. The most common clinical presentation of Alpha-1 Deficiency is lung disease. That is the reason it is also called "Inherited Emphysema" or "Genetic COPD".

High Quality Pharmaceuticals

Alpha-1

Kamada Highlights Video